Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 17Melanoma 3Glioma 3Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Multiple Endocrine Neoplasia Type 1 2Diffuse Intrinsic Pontine Glioma 2Thymus Neoplasms 1Teratoma 1Solid Tumors Harboring a BRAF V600 Mutation 1Rhabdoid Tumor 1Osteitis Deformans 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Mesothelioma 1Medulloblastoma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Glioblastoma 1Familial ependymoma 1Fallopian Tube Neoplasms 1Estrogen Receptor and/or Progesterone Receptor Positive 1Cystadenocarcinoma, Serous 1Carcinoma, Hepatocellular 1

Interventions

pralsetinib 2pembrolizumab 2Brentuximab Vedotin 2Bevacizumab 2ribociclib 1fosaprepitant 1Sunitinib 1Sirolimus 1Radiotherapy, Image-Guided 1Plicamycin 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Genistein 1Gemcitabine 1Erlotinib Hydrochloride 1Dexamethasone 1Cisplatin 1Carboplatin 1Aprepitant 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Germ Cell and Embryonal × ribociclib × Clear all
NCT02300987 2020-10-26

A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression

Novartis

Phase 2 Completed
10 enrolled 12 charts

Neoplasms, Germ Cell and Embryonal, Teratoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡